<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818671</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-2002</org_study_id>
    <nct_id>NCT04818671</nct_id>
  </id_info>
  <brief_title>Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis</brief_title>
  <acronym>ADAPTSC+</acronym>
  <official_title>A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and tolerability of&#xD;
      efgartigimod PH20 SC 1000 mg, and the clinical efficacy, PD, pharmacokinetics (PK),&#xD;
      immunogenicity, impact on the quality of life (QoL) of the participants, treatment&#xD;
      satisfaction, and administration method preference, and the feasibility of self- and&#xD;
      caregiver-supported administration of the SC injection.&#xD;
&#xD;
      Study details include: Study duration: 2 years&#xD;
&#xD;
      Treatment duration: 3-week treatment periods, repeated as needed with at least 28 days in&#xD;
      between treatment periods&#xD;
&#xD;
      Health measurements: total levels of immunoglobulin G (IgG), Acetylcholine receptor binding&#xD;
      autoantibodies (AChR-Ab) levels, Myasthenia Gravis Activities of Daly Living (MG-ADL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events (AEs)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myasthenia Gravis Activities of Daily Living (MG-ADL) total score changes from baseline</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>the higher the score, the more impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle baseline over time by cycle (for MG-ADL)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in levels of total immunoglobulin G (IgG) from baseline</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle baseline over time by cycle (for total immunoglobulin G (IgG)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of anti-acetylcholine receptor antibodies (AChR-Ab) from baseline</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle baseline over time by cycle in AChR-Ab seropositive participants (for acetylcholine receptor binding autoantibodies (AChR-Ab))</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efgartigimod serum concentrations</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs) to efgartigimod over time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of anti-drug antibodies (ADAs) to efgartigimod over time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutralizing antibodies (NAbs) against efgartigimod over time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of neutralizing antibodies (NAbs) against efgartigimod over time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADAs to rHuPH20 over time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of ADAs to rHuPH20 over time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of NAbs against rHuPH20 over time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of NAbs against rHuPH20 over time</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total Myasthenia Gravis Quality of Life Questionnaire (15-item scale revised) (MG-QoL15r) from baseline</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle baseline by cycle (for MG-QoL15r)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EuroQoL 5 Dimensions 5-Level (EQ-5D-5L) visual analog scale (VAS) score from baseline</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle baseline by cycle (for EQ-5D-5L)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L responses over time by cycle</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who performed self-administration at home over time by cycle</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who performed self-administration at home over time by cycle</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of caregivers who administered the injection to the participant at home over time by cycle</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of caregivers who administered the injection to the participant at home over time by cycle</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of training visits needed for the participant or caregiver to be competent to start administering efgartigimod PH20 SC</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of self- or caregiver-supported study drug administration among all study treatment visits at home</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of self- or caregiver-supported study drug administration among all study treatment visits at home</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Generalized Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving efgartigimod PH20 subcutaneous (SC) treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod PH20 SC</intervention_name>
    <description>Subcutaneous injection with efgartigimod PH20 SC</description>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol.&#xD;
&#xD;
          2. Previously participated in antecedent studies ARGX-113-2001 or ARGX-113-1705 and are&#xD;
             eligible for roll over.&#xD;
&#xD;
          3. Contraceptive use by men and women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies&#xD;
             and:&#xD;
&#xD;
               1. Male participants:&#xD;
&#xD;
                  - Male participants are not allowed to donate sperm from signing the informed&#xD;
                  consent (ICF) until the end of study.&#xD;
&#xD;
               2. Female participants:&#xD;
&#xD;
                    -  Women of Child bearing potential (WOCBP) must have a negative urine&#xD;
                       pregnancy test at baseline before investigational medicinal product (IMP)&#xD;
                       can be administered.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The participant was discontinued early from studies ARGX-113-2001 or ARGX-113-1705,&#xD;
             unless the reason for discontinuation from study ARGX-113-1705 was to roll over into&#xD;
             study ARGX-113-2002.&#xD;
&#xD;
             a. Participants who, in the investigator's judgment, are not benefiting from&#xD;
             efgartigimod IV in study ARGX-113-1705 Part B are not eligible for roll over into&#xD;
             ARGX-113-2002.&#xD;
&#xD;
          2. Are pregnant or lactating, or intend to become pregnant during the study or within 90&#xD;
             days after the last dose of investigational medicinal product (IMP)&#xD;
&#xD;
          3. Has any of the following medical conditions:&#xD;
&#xD;
               1. Clinically significant uncontrolled chronic bacterial, viral, or fungal infection&#xD;
                  at screening&#xD;
&#xD;
               2. Any other known autoimmune disease that, in the opinion of the investigator,&#xD;
                  would interfere with accurate assessment of clinical symptoms of myasthenia&#xD;
                  gravis or put the participant at undue risk&#xD;
&#xD;
               3. History of malignancy unless deemed cured by adequate treatment with no evidence&#xD;
                  of reoccurrence for ≥3 years before the first administration of investigational&#xD;
                  medicinal product (IMP).&#xD;
&#xD;
                  Participants with the following cancers can be included at any time:&#xD;
&#xD;
                    -  adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
                    -  carcinoma in situ of the cervix&#xD;
&#xD;
                    -  carcinoma in situ of the breast&#xD;
&#xD;
                    -  incidental histological findings of prostate cancer (TNM classification of&#xD;
                       malignant tumors stage T1a or T1b)&#xD;
&#xD;
               4. Clinical evidence of other significant serious diseases, or the participant has&#xD;
                  had a recent major surgery, or who have any other condition that, in the opinion&#xD;
                  of the investigator, could confound the results of the study or put the&#xD;
                  participant at undue risk&#xD;
&#xD;
          4. Received a live-attenuated vaccine within 28 days prior to study entry or plan to&#xD;
             receive a live-attenuated vaccine during the study&#xD;
&#xD;
          5. A known hypersensitivity reaction to efgartigimod, rHuPH20, or any of its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Guglietta, MD</last_name>
    <phone>+1 857-350-4834</phone>
    <email>ClinicalTrials@argenx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator site 6 - US0010032</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 4 - US0010110</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 7 - US0010008</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 5 - BE0320007</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 24 - CZ4200005</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 2 - GEO9950002</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1 - GEO9950001</name>
      <address>
        <city>Tbilisi</city>
        <zip>0114</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 3 - GEO9950003</name>
      <address>
        <city>Tbilisi</city>
        <zip>0114</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 25 - DE490006</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 26 - DE490009</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 10 - HU0360013</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 9 - HU0360012</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 11 - IT0390003</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 12 - JP0810002</name>
      <address>
        <city>Chiba</city>
        <state>Chiba-Shi</state>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 8 - JP0810004</name>
      <address>
        <city>Hanamaki</city>
        <state>Iwate</state>
        <zip>025-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 28- JP0810059</name>
      <address>
        <city>Ota-Ku</city>
        <state>Tokyo</state>
        <zip>143-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 14 - JP0810007</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 27 - JP0810008</name>
      <address>
        <city>Sapporo</city>
        <zip>060 8542</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 13 - JP0810005</name>
      <address>
        <city>Sendai-shi</city>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 15 - JP0810009</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 16 - NL0310001</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 17 - PL0480001</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 19 - PL0480007</name>
      <address>
        <city>Katowice</city>
        <zip>40-123</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 22 - PL0480024</name>
      <address>
        <city>Kraków</city>
        <zip>31-2002</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 18 - PL0480005</name>
      <address>
        <city>Kraków</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 20 - PL0480018</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 21 - PL0480022</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 29- RU0070002</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 30 - RU0070014</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-94834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 31 - ES0340038</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 23 - ES0340039</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

